In a striking strategic reversal, NovaBay Pharmaceuticals saw its shares surge nearly 19% on Monday following a bold announcement: the company will rebrand as Stablecoin Development Corporation and pivot its entire business model toward the stablecoin economy. The stock, which trades under the ticker NBY, jumped to $1.38 in the immediate aftermath of the news. This rebrand, which includes a new ticker symbol SDEV effective April 3, signals a definitive break from the company’s two-decade history as a biopharmaceutical firm.
CEO Michael Kazley framed the move as a response to what the company sees as the most significant structural opportunity in digital finance. “The name change to Stablecoin Development Corporation reflects our conviction that stablecoins represent the most compelling structural opportunity in digital finance,” Kazley stated. The announcement adds to a growing trend of traditional companies, particularly those with limited operating scale, seeking a new lease on life through cryptocurrency-centric strategies, even as broader crypto markets have declined since October 2023.
From Eye Care to On-Chain Holding Company
Founded in 2000 as a California-based developer of eye care products, NovaBay’s transformation was first hinted at in a January SEC filing. That document outlined a plan to operate under an “on-chain holding company framework focused on long-duration participation in protocol-level digital asset ecosystems.” The pivot was financially enabled by a $134 million private placement backed by Tether Investments, an affiliate of the stablecoin issuer Tether. This capital is designated for acquiring and holding assets within specific blockchain protocol ecosystems.
The most immediate and concrete manifestation of this new strategy is the company’s substantial holdings in the SKY token. As disclosed, NovaBay holds over two billion SKY tokens as of March 16, a position representing more than 8% of the token’s total supply. According to data from CoinGecko, SKY was trading at approximately $0.073 at the time of writing, placing the nominal value of this holding in the tens of millions of dollars. Furthermore, the company reported it has already generated cumulative staking rewards of 26.6 million SKY tokens from these holdings.
Following its name rebrand and SKY holdings disclosure, shares in NovaBay Pharmaceuticals jumped nearly 19%. Source: Google Finance
Strategic Focus on Yield-Bearing Stablecoins
While SKY is currently the only digital asset formally approved under the company’s operating and risk management framework, NovaBay’s public statements point to a broader thesis. The company explicitly identified “stablecoins as an increasingly important component of global digital financial infrastructure” and expressed particular interest in yield-bearing stablecoins.
In its announcement, NovaBay described these instruments as “a compelling evolution in digital finance, functioning as productive financial assets that unlock new primitives for savings, treasury management, and capital formation.” This language suggests the company aims to position itself not merely as a passive holder of digital assets, but as an entity seeking to generate yield through staking or other protocol-level activities, a common strategy in decentralized finance (DeFi). The company also indicated it continues to evaluate opportunities to acquire additional SKY tokens on the open market.
This dramatic pivot comes with notable risks. While the immediate market reaction was positive, the broader cryptocurrency market remains in a downturn period from its 2021 peaks. Analysts have warned that a prolonged slump could lead to industry consolidation, potentially impacting the value and liquidity of protocol-specific tokens like SKY. The success of Stablecoin Development Corporation will now be tightly linked to the adoption, stability, and economic design of the SKY protocol and the broader stablecoin sector it targets.
